CA2903255C - Modified docetaxel liposome formulations - Google Patents

Modified docetaxel liposome formulations Download PDF

Info

Publication number
CA2903255C
CA2903255C CA2903255A CA2903255A CA2903255C CA 2903255 C CA2903255 C CA 2903255C CA 2903255 A CA2903255 A CA 2903255A CA 2903255 A CA2903255 A CA 2903255A CA 2903255 C CA2903255 C CA 2903255C
Authority
CA
Canada
Prior art keywords
lipid
mol
peg
liposomes
docetaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2903255A
Other languages
English (en)
French (fr)
Other versions
CA2903255A1 (en
Inventor
William Mcghee
James Blackledge
Margaret Grapperhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt LLC
Original Assignee
Mallinckrodt LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt LLC filed Critical Mallinckrodt LLC
Publication of CA2903255A1 publication Critical patent/CA2903255A1/en
Application granted granted Critical
Publication of CA2903255C publication Critical patent/CA2903255C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2903255A 2013-03-13 2014-03-13 Modified docetaxel liposome formulations Expired - Fee Related CA2903255C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779902P 2013-03-13 2013-03-13
US61/779,902 2013-03-13
PCT/US2014/026483 WO2014160392A1 (en) 2013-03-13 2014-03-13 Modified docetaxel liposome formulations

Publications (2)

Publication Number Publication Date
CA2903255A1 CA2903255A1 (en) 2014-10-02
CA2903255C true CA2903255C (en) 2018-08-28

Family

ID=50686145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903255A Expired - Fee Related CA2903255C (en) 2013-03-13 2014-03-13 Modified docetaxel liposome formulations

Country Status (8)

Country Link
US (1) US20140271822A1 (https=)
EP (1) EP2968145A1 (https=)
JP (3) JP6294456B2 (https=)
CN (1) CN105188675A (https=)
BR (1) BR112015022819A8 (https=)
CA (1) CA2903255C (https=)
MX (1) MX2015012201A (https=)
WO (1) WO2014160392A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188675A (zh) * 2013-03-13 2015-12-23 马林克罗特有限公司 经修饰多西他赛脂质体制剂
CN104622810B (zh) * 2015-02-15 2018-06-08 中国药科大学 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
CN107613962B (zh) 2015-04-02 2021-02-09 纽约州立大学研究基金会 血清稳定组合物和用于光触发的材料释放的方法
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
WO2017120586A1 (en) * 2016-01-07 2017-07-13 Western University Of Health Sciences Formulations for treating bladder cancer
SG11201807148RA (en) * 2016-03-16 2018-09-27 Merrimack Pharmaceuticals Inc Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
CA3016383A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
US20190298681A1 (en) * 2016-03-16 2019-10-03 Merrimack Pharmaceuticals, Inc. Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics
IL264842B (en) * 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
WO2018106980A1 (en) * 2016-12-08 2018-06-14 Mallinckrodt Llc Liposomal elinafide formulations and uses thereof
US20190008987A1 (en) 2017-07-07 2019-01-10 Drexel University Voltage-Activated Therapeutic, Diagnostic, And/Or Theranostic Constructs
CN110496103B (zh) * 2018-05-18 2022-05-10 上海维洱生物医药科技有限公司 一种多西他赛棕榈酸酯脂质体及其制备方法
JP7482487B2 (ja) * 2018-09-13 2024-05-14 タイワン リポソーム カンパニー リミテッド 鎮静薬を含む徐放性医薬組成物およびその使用
TWI767149B (zh) * 2018-10-17 2022-06-11 台灣微脂體股份有限公司 含有免疫調節劑的緩釋藥物組合物及其用途
US20220265679A1 (en) * 2019-08-09 2022-08-25 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114588279B (zh) * 2022-03-31 2023-10-20 重庆医科大学附属第二医院 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用
WO2025124498A1 (zh) * 2023-12-13 2025-06-19 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物的脂质体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
WO2005079185A2 (en) * 2003-09-02 2005-09-01 Board Of Regents, The University Of Texas System Neutral liposome-encapsulated compounds and methods of making and using thereof
ATE401057T1 (de) * 2004-10-08 2008-08-15 Alza Corp Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
MX2007013200A (es) * 2005-04-22 2008-03-24 Johnson & Johnson Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2.
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
EP3415151A1 (en) * 2008-05-23 2018-12-19 The University of British Columbia Modified drugs for use in liposomal nanoparticles
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
US20120231066A1 (en) * 2011-01-24 2012-09-13 Henry John Smith Multi-drug liposomes to treat tumors
JP2014503582A (ja) * 2011-01-28 2014-02-13 コーニンクレッカ フィリップス エヌ ヴェ 親水性プロドラッグの局所放出用担体
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
CN105188675A (zh) * 2013-03-13 2015-12-23 马林克罗特有限公司 经修饰多西他赛脂质体制剂

Also Published As

Publication number Publication date
MX2015012201A (es) 2015-11-30
BR112015022819A8 (pt) 2019-11-26
EP2968145A1 (en) 2016-01-20
CN105188675A (zh) 2015-12-23
JP6294456B2 (ja) 2018-03-14
US20140271822A1 (en) 2014-09-18
JP2019006815A (ja) 2019-01-17
JP2017214433A (ja) 2017-12-07
WO2014160392A1 (en) 2014-10-02
BR112015022819A2 (pt) 2017-07-18
CA2903255A1 (en) 2014-10-02
JP2016513655A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
CA2903255C (en) Modified docetaxel liposome formulations
US10213385B2 (en) Combinational liposome compositions for cancer therapy
US20250049945A1 (en) Method of treatment for solid tumors containing hypoxia and/or stroma features
US20180344644A1 (en) Improved stability of liposome formulations and uses thereof
CA2811601A1 (en) Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US20130183236A1 (en) Mmp-targeted therapeutic and/or diagnostic nanocarriers
US20160250177A1 (en) Modified docetaxel liposome formulations and uses thereof
US20200079785A1 (en) Mitomycin c prodrug liposome formulations and uses thereof
US20210290537A1 (en) Liposomal elinafide formulations and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150831

MKLA Lapsed

Effective date: 20210913

MKLA Lapsed

Effective date: 20200313